The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?

被引:0
作者
Ruilope L.M. [1 ]
Campo C. [1 ]
Segura J. [1 ]
机构
[1] Unidad de Hipertensión, Servicio de Nefrologia, Hospital 12 de Octubre, Madrid
关键词
Proteinuria; Diabetic Nephropathy; Calcium Channel Blocker; Amlodipine; Angiotensin Converting Enzyme Inhibitor;
D O I
10.1007/s11906-001-0060-4
中图分类号
学科分类号
摘要
Chronic renal failure, proteinuria, and arterial hypertension run in parallel in the presence of diabetic nephropathy. New goal blood pressure levels have been established in diabetic patients: 130/85 mm Hg and 125/75 mm Hg depending on the level of proteinuria being below or above 1 g/d. New and lower threshold blood pressure (>130/85 mm Hg) to initiate pharmacologic therapy is required in the presence of diabetes mellitus in order to facilitate the strict blood pressure control that is required. It must be considered that both renal and cardiovascular protection are obtained with strict blood pressure control, which otherwise seems to require blockade of angiotensin II effects when proteinuria above 1 g/d is present. While awaiting the publication of long-term follow-up studies looking at renal and cardiovascular outcome in diabetic and other nephropathies in which calcium channel blockers are compared with other antihypertensive drugs, calcium channel blockers will remain the drugs needed to attain the expected goal blood pressure in diabetics, both alone (in the absence of microalbuminuria or macroalbuminuria) or in combination, particularly with angiotensin converting enzyme inhibitors. Copyright © 2001 by Current Science Inc.
引用
收藏
页码:419 / 421
页数:2
相关论文
共 21 条
  • [1] Nelson R.G., Knowler W.C., Pettit D.J., Bennett P.H., Kidney disease in diabetes, Diabetes in America, pp. 349-400, (1995)
  • [2] Parving H.H., Smidt U.M., Hommel E., Et al., Effective antihyper-tensive treatment postpones renal insufficiency in diabetic nephropathy, Am J Kidney Dis, 22, pp. 188-197, (1993)
  • [3] Ruilope L.M., Campo C., Rodicio J.L., Blood pressure control, proteinuria and renal outcome in chronic renal failure, Curr Opin Nephrol Hypertens, 7, pp. 145-148, (1998)
  • [4] Weidman P., Schneider M., Bohlen L., Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated metaanalysis, Nephrol Dial Transplant, 10, SUPPL. 9, pp. 39-45, (1995)
  • [5] The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, Arch Intern Med, 157, pp. 2413-2428, (1997)
  • [6] Guidelines subcommittee: 1999 world health organization-international society of hypertension guidelines for the management of hypertension, J Hypertens, 11, pp. 905-918, (1999)
  • [7] Ruilope L.M., Renoprotection and renin-angiotensin system blockade in diabetes mellitus, Am J Hypertens, 10, (1997)
  • [8] Tarif N., Bakris G.L., Preservation of renal function: The spectrum of effects by calcium channel blockers, Nephrol Dial Transplant, 12, pp. 2244-2250, (1997)
  • [9] Locatelli F., Marcelli D., Cornelli M., Et al., Proteinuria and blood pressure as casual components of progression to endstage renal failure, Nephrol Dial Transplant, 11, pp. 461-467, (1996)
  • [10] Ruilope L.M., Hansson L., Zanchetti A., Renal aspects of the HOT study, J Nephrol, 9, pp. 147-151, (1996)